Efficacy and Safety of Intravenous Thrombolysis in Branch Atheromatous Disease

Recruiting Observational Study
Stroke Thrombolysis DAPT(Dual Antiplatelet Therapy) SAPT(Single Antiplatelet Therapy) Acute Ischemic Stroke
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
462 (estimated)
Sponsor
Sigmund Freud PrivatUniversitat · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Rationale and Relevance: Branch Atheromatous Disease (BAD) describes an atherosclerotic occlusion of one of the deep penetrating cerebral arteries, including the lenticulostriate artery (LSA), paramedian pontine artery (PPA), and anterior choroidal artery (ACHA). BAD is frequently associated with early neurological deterioration (END), particularly progressive motor deficits that contribute to in…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * aged over 18 years, with acute ischemic stroke and symptom onset no more than 24 hours before admission, who were treated in one of the stroke units of the participating institutions. * All enrolled patients must have undergone a cerebral MRI for inclusion: 1. DWI lesion: s…
Contacts

Julian Frederic Hotz, DDr.

+43 1 211210

julian.hotz@meduniwien.ac.at

CONTACT

Marek Sykora, Prof. Dr.

+43 1 211210

marek.sykora@bbwien.at

CONTACT